România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gedeon richter romania s.a. - romania - fenspiridum - compr. elib. prel. - 80mg - alte med. pt. trat. bolilor obstructive ale c.r, sistemice alte med. pt. trat. bolilor obstructive ale c.r, sistemice

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

gedeon richter plc - fenspiridi hydrochloridum - comprimate cu eliberare prelungita - 80 mg

Uniunea Europeană - română - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mielom multiplu - agenți antineoplazici - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

novartis pharma ag - carbamazepinum - comprimate - 200 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

lekpharm srl - ambroxolum - comprimate - 30 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

zdorovie srl, companie farmaceutica - planta centauri + root levistici + frunze rosmarini - picaturi orale, solutie

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

zdorovie srl, companie farmaceutica - planta centauri + root levistici + frunze rosmarini - picaturi orale, solutie

Uniunea Europeană - română - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - agenți antineoplazici - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Uniunea Europeană - română - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

aop orphan pharmaceuticals gmbh - austria - treprostinilum - sol. perf. - 1mg/ml - antitrombotice antiagregante plachetare